Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid Bauer

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Cochrane Database of Systematic Reviews|November 24, 2022
Antipsychotic dose reduction compared to dose continuation for people with schizophreniaAlessandro Rodolico, Spyridon Siafis, Irene Bighelli, et al.
Archives of Neurology|September 17, 2003
Frequency and phenotypic variability of the GAG deletion of the DYT1 gene in an unselected group of patients with dystoniaKathrin Grundmann, Ulrike Laubis-Herrmann, Ingrid Bauer, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 28, 2023
Shared Decision Making Assistant (SDMA) and other digital tools for choosing antipsychotics in schizophrenia treatmentStefan Leucht, Spyridon Siafis, Alessandro Rodolico, et al.
Annals of Neurology|July 12, 2002
Trinucleotide repeat expansions in the junctophilin-3 gene are not found in Caucasian patients with a Huntington's disease-like phenotypeIngrid Bauer, Martin Gencik, Franco Laccone, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|November 19, 2022
Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trialWolfgang Strube, Aslihan Aksar, Ingrid Bauer, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 19, 2025
The ILIA study: protocol for a randomized-controlled multicenter clinical trial on smartphone- and web-based relapse monitoring for patients with schizophrenia or schizoaffective disorderSelina Hiller, Laura Emde, Denise Jais, et al.
Pharmacopsychiatry|July 28, 2023
Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric TrialElias Wagner, Wolfgang Strube, Thomas Görlitz, et al.
Human Molecular Genetics|March 7, 2003
Transgenic rat model of Huntington's diseaseStephan von Hörsten, Ina Schmitt, Huu Phuc Nguyen, et al.
Contemporary Clinical Trials Communications|February 20, 2020
Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trialAlkomiet Hasan, Astrid Roeh, Stefan Leucht, et al.
Communications Medicine|June 16, 2026
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trialAlkomiet Hasan, Stefan Leucht, Astrid Roeh, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Cochrane Database of Systematic Reviews|November 24, 2022
Antipsychotic dose reduction compared to dose continuation for people with schizophreniaAlessandro Rodolico, Spyridon Siafis, Irene Bighelli, et al.
Archives of Neurology|September 17, 2003
Frequency and phenotypic variability of the GAG deletion of the DYT1 gene in an unselected group of patients with dystoniaKathrin Grundmann, Ulrike Laubis-Herrmann, Ingrid Bauer, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 28, 2023
Shared Decision Making Assistant (SDMA) and other digital tools for choosing antipsychotics in schizophrenia treatmentStefan Leucht, Spyridon Siafis, Alessandro Rodolico, et al.
Annals of Neurology|July 12, 2002
Trinucleotide repeat expansions in the junctophilin-3 gene are not found in Caucasian patients with a Huntington's disease-like phenotypeIngrid Bauer, Martin Gencik, Franco Laccone, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|November 19, 2022
Effects of add-on Celecoxib treatment on patients with schizophrenia spectrum disorders and inflammatory cytokine profile trial (TargetFlame): study design and methodology of a multicentre randomized, placebo-controlled trialWolfgang Strube, Aslihan Aksar, Ingrid Bauer, et al.
European Archives of Psychiatry and Clinical Neuroscience|August 19, 2025
The ILIA study: protocol for a randomized-controlled multicenter clinical trial on smartphone- and web-based relapse monitoring for patients with schizophrenia or schizoaffective disorderSelina Hiller, Laura Emde, Denise Jais, et al.
Pharmacopsychiatry|July 28, 2023
Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric TrialElias Wagner, Wolfgang Strube, Thomas Görlitz, et al.
Human Molecular Genetics|March 7, 2003
Transgenic rat model of Huntington's diseaseStephan von Hörsten, Ina Schmitt, Huu Phuc Nguyen, et al.
Contemporary Clinical Trials Communications|February 20, 2020
Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trialAlkomiet Hasan, Astrid Roeh, Stefan Leucht, et al.
Communications Medicine|June 16, 2026
Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trialAlkomiet Hasan, Stefan Leucht, Astrid Roeh, et al.
Pageof 2